COPAXONE® (glatiramer acetate injection) 40 mg/mL Logo
Shared Solutions®
Copaxone® is the #1 prescribed brand for relapsing MS in the US 1*

For patients with relapsing multiple sclerosis (RMS)


An immunomodulator with demonstrated efficacy, safety, and tolerability.1

Teva is your partner in the care of relapsing MS.


As you consider your treatment goals for your relapsing MS patients— now and in years to come—you can count on Teva and COPAXONE®.

Two people taking a walk

Trusted support

Teva's Shared Solutions® can take care of many important behind-the-scenes details so you can focus on treating your patients.


Financial support

Teva is committed to helping your patients find financial solutions to start and stay on COPAXONE® treatment. Teva's Shared Solutions® offers a range of services to help COPAXONE® 40 mg/mL patients gain access to therapy. A $0 monthly co-pay is available for eligible patients.*


CNE and Field Nursing

Call on Shared Solutions® and Teva Field Nursing to be your partners for patient training, education, and support for Teva products. Our nationwide team is dedicated to supporting COPAXONE® patient compliance and care.

Two people enjoying the sunset

COPAXONE® Tolerability

In a 3-times-a-week COPAXONE® 40 mg/mL clinical trial,1 91% of patients treated with COPAXONE® 40 mg/mL stayed on therapy for over 12 months. Approximately 3% of patients treated with COPAXONE® 40 mg/mL discontinued treatment due to an adverse event.

of patients who stayed on therapy for over 12 months

The leading therapy for RMS

COPAXONE® is the #1 prescribed brand in the US since 2008.8†‡

Based on prescriptions for the market definition of disease-modifying therapies for relapsing forms of multiple sclerosis in the US (IMS Health National Prescription Audit, March 2017). All Rights Reserved by IMS.

The COPAXONE® brand represents 40 mg/mL and 20 mg/mL combined prescriptions.

A photo showing how COPAXONE® is thought to work

The COPAXONE® mechanism of action

An immunoactive mixture of synthesized polypeptides, COPAXONE® is thought to work by modifying immune processes that are believed to be responsible for the pathogenesis of RMS. The mechanism(s) by which COPAXONE® exerts its effect in patients with RMS are not fully understood. COPAXONE® can modify immune functions, and concerns exist about its potential to alter naturally-occurring immune responses. There is no evidence that COPAXONE® does this, but this has not been systematically evaluated.1,2,3


3-times-a-week dosing1

Our history of innovation continued with the approval of
3-times-a-week COPAXONE® 40 mg/mL in 2014, giving relapsing MS patients the option of 208 fewer injections per year compared with daily COPAXONE® 20 mg/mL. Today, COPAXONE® remains the #1 RMS brand in the US.1


COPAXONE® is an immunoactive mixture of synthesized polypeptides consisting of four naturally occurring amino acids.

Rigorously tested clinical profile

Teva rigorously tested COPAXONE® in 5 clinical trials between 1987 and 2013, demonstrating it to be an effective, safe, and tolerable choice for relapsing MS treatment.


3-times-a-week COPAXONE®  40 mg/mL significantly reduced relapses at 1 year1,7

Annualized relapse rate (ARR)1,7


Pioneering support for the relapsing MS community

The first-of-its-kind support program for the MS community, Teva's Shared Solutions® began in 1997. The program has evolved over the years to include personalized and innovative services and tools for Teva's COPAXONE® patients and healthcare practices.


A history of scientific innovation

In the 1960s, Drs. Michael Sela and Ruth Arnon of the Weizmann Institute of Science in Rehovot, Israel, discovered copolymer 1 (now known as COPAXONE®).4 They went on to study its effectiveness in suppressing MS-like disease in animal models. The development of COPAXONE® continued through the 1970s and 1990s,4-6 and it was approved for RRMS in 1996.1

20 years: COPAXONE® (glatiramer acetate injection) approved in 1996


COPAXONE® (glatiramer acetate injection)

What’s next

Our commitment to research, advancements in care, and enhanced support continues for you and your relapsing MS patients.


  1. COPAXONE® (glatiramer acetate injection) prescribing information. Rev. 8/2016. Teva Neuroscience, Inc.
  2. Schellekens H, Klinger E, Muhlebach S, et al. Regul Toxicol Pharmacol. 2011;59(1):176-183.
  3. Johnson KP. Expert Opin Drug Metab Toxicol. 2010;6(5):643-660.
  4. Johnson KP. The Remarkable Story of COPAXONE. New York, NY: Diamedica Publishing; 2010.
  5. Bornstein M, Miller A, Slagle S, et al. N Engl J Med. 1987;317(7):408-414.
  6. Johnson KP, Brooks BR, Cohen JA, et al. Neurology. 1995;45(7):1268-1276.
  7. Khan O, Rieckmann P, Boyko A, Selmaj K, Zivadinov R; for the GALA Study Group. Ann Neurol. 2013;73(6):705-713.
  8. IMS Health National Prescription Audit, March 2017. Data proprietary to IMS Health.

Injections for 3-times-a-week COPAXONE® 40 mg must be at least 48 hours apart.


COPAXONE® is contraindicated in patients with known hypersensitivity to glatiramer acetate or mannitol.
Approximately 16% of patients exposed to COPAXONE® 20 mg per mL compared to 4% of those on placebo, and approximately 2% of


COPAXONE® (glatiramer acetate injection) is indicated for the treatment of patients with relapsing forms of multiple sclerosis.


Important Safety Information

COPAXONE® is contraindicated in patients with known hypersensitivity to glatiramer acetate or mannitol.

Approximately 16% of patients exposed to COPAXONE® 20 mg per mL compared to 4% of those on placebo, and approximately 2% of patients exposed to COPAXONE® 40 mg per mL compared to none on placebo experienced a constellation of symptoms immediately after injection that included at least 2 of the following: flushing, chest pain, palpitations, anxiety, dyspnea, throat constriction, and urticaria. In general, these symptoms have their onset several months after the initiation of treatment, although they may occur earlier, and a given patient may experience 1 or several episodes of these symptoms. Typically, the symptoms were transient and self-limited and did not require treatment; however, there have been reports of patients with similar symptoms who received emergency medical care.

Transient chest pain was noted in 13% of COPAXONE® 20 mg per mL patients compared to 6% of placebo patients, and approximately 2% of COPAXONE® 40 mg per mL patients compared to 1% on placebo. While some episodes of chest pain occurred in the context of the immediate postinjection reaction described above, many did not. The temporal relationship of this chest pain to an injection was not always known. The pain was usually transient, often unassociated with other symptoms, and appeared to have no clinical sequelae. Some patients experienced more than 1 such episode, and episodes usually began at least 1 month after the initiation of treatment.

At injection sites, localized lipoatrophy and, rarely, injection site skin necrosis may occur. Lipoatrophy may occur at various times after treatment onset (sometimes after several months) and is thought to be permanent. There is no known therapy for lipoatrophy.

Because COPAXONE® can modify immune response, it may interfere with immune functions. For example, treatment with COPAXONE® may interfere with recognition of foreign antigens in a way that would undermine the body's tumor surveillance and its defenses against infection. There is no evidence that COPAXONE® does this, but there has not been a systematic evaluation of this risk.

In controlled studies of COPAXONE® 20 mg per mL, the most common adverse reactions with COPAXONE® vs placebo were injection site reactions (ISRs), such as erythema (43% vs 10%); vasodilatation (20% vs 5%); rash (19% vs 11%); dyspnea (14% vs 4%); and chest pain (13% vs 6%).

In a controlled study of COPAXONE® 40 mg per mL, the most common adverse reactions with COPAXONE® vs placebo were ISRs, such as erythema (22% vs 2%).

ISRs were one of the most common adverse reactions leading to discontinuation of COPAXONE®. ISRs, such as erythema, pain, pruritus, mass, edema, hypersensitivity, fibrosis, and atrophy, occurred at a higher rate with COPAXONE® than placebo.

Please see full Prescribing Information for COPAXONE®.

You are now leaving this website

The website you are about to visit does not belong to Teva Neuroscience, Inc. or follow the same terms of service. Some of these websites may also require a third-party account, subscription, or payment to view.

While we carefully choose which websites we link to, we cannot control any changes or actions made by them. As a result, Teva makes no warranties or representations of any kind as to the accuracy, currency, or completeness of the following site, nor any liability on their behalf.

Continue to site